{
  "ticker": "PNV",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02973992",
  "id": "02973992",
  "pages": 4,
  "price_sensitive": true,
  "date": "20250729",
  "time": "1638",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250729/pdf/06m8hcl91jxpph.pdf",
  "summary": "### **PolyNovo Limited \u2013 ASX Announcement Summary (29 July 2025)**  \n\n#### **Material Information for Capital Markets:**  \n1. **FY25 Financial Highlights (Unaudited):**  \n   - **Closing Cash (30 June 2025):** A$33.5m (vs. A$22.0m at 31 March 2025).  \n   - **2H25 Operating Cash Flow:** A$15.7m (vs. 1H25 outflow of -A$12.5m).  \n   - **FY25 EBITDA:** A$11.2m\u2013A$12.4m (vs. STLY A$3.6m).  \n   - **Total FY25 Sales:** A$118.6m (+28.9% YoY).  \n     - **U.S. Sales:** A$88.4m (+28.7% YoY).  \n     - **Rest of World:** A$30.3m (+29.6% YoY).  \n\n2. **Growth Drivers:**  \n   - Record monthly sales in June 2025 (A$13.7m revenue).  \n   - **NovoSorb MTX Sales:** A$6.7m in FY25 (A$2.1m in 1H, A$4.6m in 2H).  \n   - Expansion into 46 countries, with new markets (Malaysia, Czech Republic, etc.).  \n\n3. **Capital & Liquidity:**  \n   - **Upcoming Capex (FY26):** A$8.5m for new facility (A$6.9m funded via U.S. debtors).  \n   - **Equipment Finance Facility:** A$7.5m available (A$3.2m drawn).  \n\n4. **Regulatory/Clinical Developments:**  \n   - **510(k) clearance** for NovoSorb BTM (up to 6mm thickness).  \n   - Collaboration with Beta Cell Technologies for cell therapy trials.  \n\n#### **Next Key Date:**  \n- **FY25 Audited Results:** 25 August 2025.  \n\n*Omitted: Webinar details, chairman/CEO commentary, non-material operational updates.*",
  "usage": {
    "prompt_tokens": 1889,
    "completion_tokens": 465,
    "total_tokens": 2354,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-29T06:45:01.294874"
}